Prenolica (formerly Solagran) is an Australian Biotech company founded in 1995.
The company’s primary focus is the research, development and production of a range of unique biologically active substances known as Bioeffectives.
Bioeffectives are obtained using world first patented technology. It allows for the isolation of “live elements” of green biomass, mainly conifers, in a way that both preserves and amplifies their biological activity as balanced, synergistic complexes, particularly polyprenols.
They are multi-molecule natural substances, which have multiple applications with the advantage of few; if-any side effects.
The Bioeffectives research program spans almost 90 years. It has resulted in the development of a number of commercialised products world-wide including a natural pharmaceutical for the treatment of liver disease.
Prenolica believes the use of Bioeffectives in medicine offers a new approach with the ability to prevent many chronic illnesses and result in real and sustainable improvements in health outcomes globally.
It should also be noted that their use in agriculture and animal husbandry can enhance the integrity of the human food chain by reducing the need for toxic pesticides and antibiotics.
Consistent with the wishes of those who started the Bioeffectives research program in the 1930’s, and those who are continuing this legacy, our primary focus is to improve the health and wellbeing of mankind.